



25 Julai 2019
25 July 2019
P.U. (A) 207

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN
(PINDAAN SENARAI RACUN) (NO. 3) 2019

*POISONS (AMENDMENT OF POISONS LIST)
(NO. 3) ORDER 2019*

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 3) 2019

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 3) 2019**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan menggantikan butiran “Adenosine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Adenosine	-	-	Medicinal preparations unless exempted	All preparations unless in Group C or exempted	-	Adenosine in— (1) raw cordyceps (2) product which is registered under the Control of Drugs and Cosmetics Regulations 1984 containing adenosine from natural resources (3) cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984 (4) food”;

- (ii) dengan menggantikan butiran “N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H- indazole- 3- carboxamide (AB-CHMINACA)” dengan butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)”;
- (iii) dengan memasukkan selepas butiran “2-Amino-1-(2, 5-dimethoxy-4- methyl) phenylpropane (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl- 1H-indazole-3-carboxamide (AB-PINACA) (DD)	-	All preparations”;				

- (iv) dengan menggantikan butiran “Ammonia” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ammonia	-	-	-	-	5% and above	(1) Below 5% (2) Ammonia inside cooling units of a refrigerator, air conditioner and smelling bottles (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (v) dengan memasukkan selepas butiran “Apraclonidine; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Apremilast	-	All preparations”;					

- (vi) dengan menggantikan butiran “Azelaic Acid” dan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Azelaic Acid	-	All medicinal preparations unless in Group C	Medicinal preparations for external use		All preparations unless in Group B or Group C”;	

- (vii) dengan menggantikan butiran “Bismuth; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bismuth; its salts	-	All medicinal preparations unless in Group C or exempted	Suppositories and medicinal preparations for external use unless exempted	All preparations unless in Group B, Group C or exempted	-	Cosmetics including those for the eye, containing bismuth oxychloride as a pearling or colouring agent”;

- (viii) dengan menggantikan butiran “Caffeine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Caffeine	-	-	-	-	All preparations (1) Caffeine in— unless exempted	

(i) food or beverages

(ii) cosmetic which is notified
under the Control of Drugs and
Cosmetics Regulations 1984

(iii) product which is registered
under the Control of Drugs and
Cosmetics Regulations 1984

(2) Its analogues, homologues,
compounds, intermediates,
derivatives, esters, ethers,
salts and other substances
structurally derived”;

(ix) dengan memotong butiran “Carfentanil citrate” dan butir-butir yang berhubungan dengannya;

(x) dengan menggantikan butiran “Chloroform” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Chloroform preparations for food-producing animals	Veterinary	-	Medicinal preparation unless in Group A or exempted	All preparation unless in Group A, Group C or exempted	-	Strengths under 10% unless Group A";

(xi) dengan menggantikan butiran "Creosote, obtained from wood" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Creosote, obtained from wood	-	-	-	-	Strengths over 50%	(1) Strengths of 50% and under (2) Its analogues, homologues, compounds, intermediates,

derivatives, esters, ethers,
salts and other
substances structurally
derived”;

- (xii) dengan memasukkan selepas butiran “Dimethoxybromoamphetamine (DOB) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2,5-dimethoxy- α ,4-dimethylphenethylamine (STP/DOM) (DD)	-	All preparations”;				

- (xiii) dengan menggantikan butiran “Dinitronaphthols” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Dinitronaphthols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xiv) dengan menggantikan butiran "Dinitrophenols" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Dinitrophenols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

- (xv) dengan menggantikan butiran “Dinitrothymols” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dinitrothymols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xvi) dengan menggantikan butiran “Flunitrazepam; its salts (DD)” dengan butiran “Flunitrazepam (DD)”;
- (xvii) dengan memasukkan selepas butiran “Fluorides, alkali; organo fluorides” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“4-Fluoroamphetamine (4-FA) (DD)	-	All preparations”;				

- (xviii) dengan menggantikan butiran “Formaldehyde” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Formaldehyde	-	-	-	-	5% and over calculated as HCHO	(1) Under 5% calculated as HCHO (2) Photographic glazing or hardening solution (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xix) dengan menggantikan butiran “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item” dengan butiran “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item, for therapeutic use”;

- (xx) dengan menggantikan butiran “Hydrochloric acid” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydrochloric acid; hydrogen chloride	-	-	-	-	9% and over calculated as HCl	(1) Under 9% calculated as HCl (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xxi) dengan menggantikan butiran “Hydrogen bromide” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydrogen bromide;	-	-	-	-	All preparations	(1) Preparations ready for use as pesticides

hydrobromic acid

unless
exempted(2) Its analogues, homologues,
compounds, intermediates,
derivatives, esters, ethers, salts
and other substances
structurally derived”;

- (xxii) dengan menggantikan butiran “Hydrofluoric acid” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydrofluoric acid; hydrogen fluoride	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xxiii) dengan menggantikan butiran “Hydroquinone” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Hydroquinone	-	-	All medicinal preparations unless exempted	-	All preparations unless in Group C or exempted	<p>(1) Artificial nail systems which is a notified cosmetic under the Control of Drugs and Cosmetics Regulations 1984, containing hydroquinone not more than 0.02% w/w</p> <p>(2) Notified cosmetic under the Control of Drugs and Cosmetics Regulations 1984 containing arbutin</p> <p>(3) Its analogues, homologues, compounds, intermediates,</p>

derivatives, esters,
ethers, salts and other
substances structurally
derived”;

- (xxiv) dengan menggantikan butiran “Isoniazid; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Isoniazid; its salts	-	-	All medicinal preparations	All preparations unless in Group C”;		

- (xxv) dengan menggantikan butiran “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds: Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine	All condoms or preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use (2) Suppositories, lozenges and pastilles (3) Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic	Preparations for laboratory use”;	

Diperodon
 Etidocaine
 Lignocaine
 Levobupivacaine
 Mepivacaine
 Orthocaine
 Oxethazaine
 Phenacaine
 Phenodanisyl
 Prilocaine
 Ropivacaine
 Tetracaine

(xxvi) dengan menggantikan butiran “Mercury” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mercury	-	-	-	All preparations unless	-	(1) Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984

exempted

containing not more than 1 part per million of mercury calculated as the metal

- (2) Product which is registered under the Control of Drugs and Cosmetics Regulations 1984 containing not more than 0.5 part per million of mercury calculated as the metal

(3) Appliances containing mercury”;

(xxvii) dengan memasukkan selepas butiran “Methyl bromide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)	-	All preparations”;			

- (xxviii) dengan memasukkan selepas butiran “Miconazole; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Midostaurin	-	All preparations”;					

- (xxix) dalam butiran “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers-”—

- (A) dengan memasukkan selepas butiran “(DD) Acetylmethadol” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Acryloylfentanyl	-	All preparations”;					

(B) dengan memasukkan selepas butiran “(DD) Betameprodine” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Betamethadol	-	All preparations”;				

(C) dengan memasukkan selepas butiran “(DD) Cannabis, its resin, extracts and tinctures of; cannabin tannate” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Carfentanil	-	All preparations”;				

(D) dengan memasukkan selepas butiran “(DD) Fentanyl” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)	-	All preparations				
(DD) Furanyl fentanyl	-	All preparations”;				

(E) dengan memasukkan selepas butiran “(DD) Norpipanone” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Ocfentamil	-	All preparations”;				

(F) dengan menggantikan butiran “(DD) Racemethorplan” dengan butiran “(DD) Racemethorphan”;

(G) dengan memasukkan selepas butiran “(DD) Sufentamil” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

	<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
		<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
	“(DD) Tetrahydrofuranyl fentanyl (THF-F)	-	All preparations”;				
(xxx)	dengan menggantikan butiran “Nimetazepam; its salts (DD)” dengan butiran “Nimetazepam (DD)”;						
(xxxi)	dengan menggantikan butiran “Nitric acid” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:						

	<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
		<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
	“Nitric acid	-	-	-	-	9% w/w and over	(1) Under 9% w/w (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xxxii) dengan memasukkan selepas butiran “Pentoxifylline” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)	-	All preparations”;				

- (xxxiii) dengan menggantikan butiran “Phenols (any member of the series of phenols of which the first member is phenol) and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” dan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phenols (any member of the series of phenols of which the first member is phenol and	-	-	All preparations for diagnostic or therapeutic	-	All preparations other than those in Part I	(1) Paratertiary amyl phenol; tertiary butyl cresol; thymol; carvacrol; soap; tar (coal or wood); essential

of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal

use unless exempted

or exempted

oils; essential oils in which phenols occur naturally

(2) Strengths under 2.5% w/w of phenols

(3) 5% w/w of phenols or under in surgical dressings for human or animal use

(4) Its analogues, homologues, compounds (other than compounds of phenol with a metal), intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxxiv) dengan menggantikan butiran “Phosphorus” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Phosphorus white, yellow, red or black	-	-	-	-	All preparations unless exempted	(1) Phosphorus in food, notified cosmetic or registered product under the Control of Drugs and Cosmetics Regulations 1984 (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xxxv) dengan menggantikan butiran "Potassium hydroxide" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Potassium hydroxide	-	-	-	-	12% and over unless	(1) Under 12% (2) Accumulators, batteries or when use as

exempted food additive in food

(3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xxxvi) dengan menggantikan butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)” dengan butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) (DD)”;
- (xxxvii) dengan menggantikan butiran “Safrole” dengan butiran “Safrole; includes safrole-rich oil”;
- (xxxviii) dengan memasukkan selepas butiran “Selenium sulphide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Selexipag	-	All preparations”;				

- (xxxix) dengan menggantikan butiran “Sodium hydroxide” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Sodium hydroxide"	-	-	All preparations for therapeutic or diagnostic use	-	All preparations containing 12% and over other than those in Part I or exempted and subject to the provisions of Poisons (Sodium Hydroxide) Regulations, 1962	(1) Under 12% (2) Sodium hydroxide when use as food additive in food (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xl) dengan menggantikan butiran "Sulphuric acid" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Sulphuric acid	-	-	-	-	9% w/w and over unless exempted	(1) Under 9% w/w (2) Accumulators; batteries; fire-extinguishers (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xli) dengan menggantikan butiran "Thallium; salts of" dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Thallium; salts of	-	All medicinal preparations	-	-	All preparations unless in Group B";	

- (xlii) dengan menggantikan butiran “Thionyl Chloride” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Thionyl Chloride	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xliii) dengan menggantikan butiran “Thiouracil and other substances structurally derived therefrom” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Thiouracil and other substances structurally derived therefrom	-	All medicinal preparations	-	All preparations unless in Group B”;		

- (xiv) dengan menggantikan butiran “L-Tryptophan” dan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“L-Tryptophan	-	All preparations unless exempted	-	-	-	(1) Preparations containing naturally occurring L-Tryptophan (2) Animal feed or feed additive (3) Food and its added nutrient”;

- (xlv) dengan menggantikan butiran “Urea” dan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Urea in medicinal preparation containing 40% and above of urea	-	-	All medicinal preparations”;			

- (xlvi) dengan menggantikan butiran “13C-Urea” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>		<i>Part II Exempt</i>	
	<i>Group A</i>	<i>Group B</i>		<i>Group C</i>
“13C-Urea in medicinal preparations	-	-	All medicinal preparations”; dan	

- (xlvii) dengan memasukkan selepas butiran “Vismodegib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Vonoprazan	-	All preparations”; dan			

- (b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai “**Analeptics and Central Stimulants**”—

- (A) dengan memasukkan sebelum butiran “Amiphenazole; its salts” butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) (DD)”; dan

- (B) dengan memasukkan selepas butiran “Fenetylline” butiran “Fluoroamphetamine (4-FA) (DD)”;
- (C) dengan memasukkan selepas butiran “Methylphenidate; its salts” butiran “Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)”;
dan
- (D) dengan memasukkan selepas butiran “Pemoline; its salts” butiran “(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)”;
- (ii) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents**”—
- (A) dengan menggantikan butiran “N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)” dengan butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)”;
- (B) dengan menggantikan butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate (5F-PB-22)” dengan butiran “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) (DD)”;
- (iii) dalam senarai “**Antidepressants**”, dengan menggantikan butiran “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha- methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item” dengan butiran “Hydrazines, benzyl, phenethyl, phenoxyethyl; their

alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item for therapeutic use”;

- (iv) dalam senarai “**Antifungals and Antiprotozoals**”, dengan menggantikan butiran “Urea” dengan butiran “Urea in medicinal preparation containing 40% and above of urea”;
- (v) dalam senarai “**Antihypertensives**”, dengan menggantikan butiran “Oxyclozanide” dengan butiran “Oxyclozanide”;
- (vi) dalam senarai “**Antineoplastic agents and Immunosuppressants**”—
 - (A) dengan memasukkan selepas butiran “Anastrozole” butiran “Apremilast”;
 - (B) dengan memasukkan selepas butiran “Methotrexate; its salts” butiran “Midostaurin”; dan
 - (C) dengan memasukkan selepas butiran “Trofosfamide” butiran “Vedolizumab”;
- (vii) dalam senarai “**Anti-ulcer agents**”, dengan memasukkan selepas butiran “Roxatidine” butiran “Vonoprazan”;
- (viii) dalam senarai “**Industrial and laboratory poisons**”—

- (A) dengan menggantikan butiran “Hydrochloric acid” dengan butiran “Hydrochloric acid; hydrogen chloride”; dan
 - (B) dengan menggantikan butiran “Safrole” dengan butiran “Safrole; includes safrole-rich oil”;
- (ix) dalam senarai “**Narcotics**” —
- (A) dengan memasukkan selepas butiran “(DD) Acetylmethadol” butiran “(DD) Acryloylfentanyl”;
 - (B) dengan memasukkan selepas butiran “(DD) Cannabis, its resin, extracts and tinctures of; cannabin tannate” butiran “(DD) Carfentanil”;
 - (C) dengan memasukkan selepas butiran “(DD) Fentanyl” butiran yang berikut:
 - “(DD) 4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)
 - (DD) Furanyl fentanyl”;
 - (D) dengan memasukkan selepas butiran “(DD) Norpipanone” butiran “(DD) Ocfentanil”;
 - (E) dengan memasukkan selepas butiran “(DD) Racemorphan” butiran “(DD) Remifentanil”; dan

- (F) dengan memasukkan selepas butiran “(DD) Sufentanil” butiran “(DD) Tetrahydrofuranyl fentanyl (THF-F)”;
- (x) dalam senarai “**Tranquillisers**”—
- (A) dengan memasukkan selepas butiran “Diazepam and other substances structurally derived from 1, 4-benzodiazepine; their salts, unless specified elsewhere in the List” butiran “1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (STP/DOM) (DD)”;
- (B) dengan menggantikan butiran “Flunitrazepam; its salts” dengan butiran “Flunitrazepam (DD)”;
- (C) dengan menggantikan butiran “Nimetazepam; its salts” dengan butiran “Nimetazepam (DD)”;
- (D) dengan menggantikan butiran “Zolzepam” dengan butiran “Zolazepam”; dan
- (xi) dalam senarai “**Miscellaneous**”—
- (A) dengan memotong butiran “Carfentanil citrate”;
- (B) dengan memotong butiran “Furazolidone”;

- (C) dengan menggantikan butiran “Phosphorus” dengan butiran “Phosphorus white, yellow, red or black”;
- (D) dengan memasukkan selepas butiran “Selenium sulphide” butiran “Selexipag”; dan
- (E) dengan menggantikan butiran “13-C Urea” dengan butiran “13C-Urea in medicinal preparations”.

Dibuat 25 Jun 2019
[KKM.R.600-1/1/56 JLD.4(8); PN(PU2)172/XVII]

DATUK SERI DR. DZULKEFLY BIN AHMAD
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 3) ORDER 2019

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [*Act 366*], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 3) Order 2019**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by substituting for the item “Adenosine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Adenosine	-	-	Medicinal preparations unless exempted	All preparations unless in Group C	-	Adenosine in— (1) raw cordyceps

or exempted

(2) product which is registered under the Control of Drugs and Cosmetics Regulations 1984 containing adenosine from natural resources

(3) cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984

(4) food”;

(ii) by substituting for the item “N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)” the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)”;

(iii) by inserting after the item “2-Amino-1-(2, 5-dimethoxy-4- methyl) phenylpropane (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl- 1H-indazole-3-carboxamide (AB-PINACA) (DD)”	-	All preparations”;				

(iv) by substituting for the item “Ammonia” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ammonia	-	-	-	-	5% and above	(1) Below 5% (2) Ammonia inside cooling units of a refrigerator, air conditioner and smelling bottles (3) Its analogues, homologues,

compounds, intermediates,
 derivatives, esters, ethers, salts
 and other substances
 structurally derived”;

(v) by inserting after the item “Apraclonidine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Apremilast	-	All preparations”;				

(vi) by substituting for the item “Azelaic Acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Azelaic Acid	-	All medicinal preparations unless in Group C	Medicinal preparations for external use	All preparations unless in Group B or Group C”;		

(vii) by substituting for the item “Bismuth; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Bismuth; its salts	-	All medicinal preparations unless in Group C or exempted	Suppositories and medicinal preparations for external use unless exempted	All preparations unless in Group B, Group C or exempted	-	Cosmetics including those for the eye, containing bismuth oxychloride as a pearling or colouring agent”;

(viii) by substituting for the item “Caffeine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Caffeine	-	-	-	-	All preparations unless exempted	(1) Caffeine in— (i) food or beverages (ii) cosmetic which is notified under the Control of Drugs and Cosmetics

Regulations 1984

(iii) product which is registered under the Control of Drugs and Cosmetics Regulations 1984

(2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(ix) by deleting the item “Carfentanil citrate” and the particulars relating to it;

(x) by substituting for the item “Chloroform” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Chloroform	Veterinary preparations for food-producing animals	-	Medicinal preparation unless in Group A or exempted	All preparation unless in Group A, Group C or exempted	-	Strengths under 10% unless Group A”;

- (xi) by substituting for the item “Creosote, obtained from wood” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Creosote, obtained from wood	-	-	-	-	Strengths over 50%	(1) Strengths of 50% and under (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

- (xii) by inserting after the item “Dimethoxybromoamphetamine (DOB) (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2,5-dimethoxy- α ,4-dimethylphenethylamine (STP/DOM) (DD)	-	All preparations”;				

(xiii) by substituting for the item “Dinitronaphthols” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dinitronaphthols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xiv) by substituting for the item “Dinitrophenols” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dinitrophenols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xv) by substituting for the item “Dinitrothymols” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dinitrothymols	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xvi) by substituting for the item “Flunitrazepam, its salts (DD)” the item “Flunitrazepam (DD)”;

(xvii) by inserting after the item “Fluorides, alkali; organo fluorides” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“4-Fluoroamphetamine (4-FA) (DD)	-	All preparations”;				

(xviii) by substituting for the item “Formaldehyde” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Formaldehyde	-	-	-	-	5% and over calculated as HCHO	(1) Under 5% calculated as HCHO (2) Photographic glazing or hardening solution (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xix) by substituting for the item “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item” the item “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item, for therapeutic use”;

(xx) by substituting for the item “Hydrochloric acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Hydrochloric acid; hydrogen chloride	-	-	-	-	9% and over calculated as HCl	(1) Under 9% calculated as HCl (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived";

(xxi) by substituting for the item "Hydrogen bromide" and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Hydrogen bromide; hydrobromic acid	-	-	-	-	All preparations unless exempted	(1) Preparations ready for use as pesticides (2) Its analogues, homologues, compounds, intermediates,

derivatives, esters, ethers,
salts and other substances
structurally derived”;

(xxii) by substituting for the item “Hydrofluoric acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydrofluoric acid; hydrogen fluoride	-	-	-	-	All preparations unless exempted	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxiii) by substituting for the item “Hydroquinone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Hydroquinone	-	-	All medicinal preparations	-	All preparations	(1) Artificial nail systems which is a notified cosmetic under the

unless
exempted

unless in
Group C or
exempted

Control of Drugs and
Cosmetics Regulations 1984,
containing hydroquinone not
more than 0.02% w/w

(2) Notified cosmetic under the
Control of Drugs and
Cosmetics Regulations 1984
containing arbutin

(3) Its analogues, homologues,
compounds, intermediates,
derivatives, esters, ethers,
salts and other substances
structurally derived”;

(xxiv) by substituting for the item “Isoniazid; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Isoniazid; its salts	-	-	All medicinal preparations	All preparations unless in Group C”;		

(xxv) by substituting for the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds: Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate	All condoms or preparations containing local anaesthetics unless in Group B, Group C or Group D	All preparations in pharmaceutical dosage forms unless in Group C	(1) All preparations in pharmaceutical dosage form for topical use in the nose, eyes and ears or external use (2) Suppositories, lozenges and pastilles (3) Preparations in the form of cartridges for dental use containing 2% or less of local anaesthetic	Preparations for laboratory use”;	

Cinchocaine
 Dipiperodon
 Etidocaine
 Lignocaine
 Levobupivacaine
 Mepivacaine
 Orthocaine
 Oxethazaine
 Phenacaine
 Phenodanisyl
 Prilocaine
 Ropivacaine
 Tetracaine

(xxvi) by substituting for the item “Mercury” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mercury	-	-	-	All preparations unless exempted	-	(1) Cosmetic which is notified under the Control of Drugs and Cosmetics Regulations 1984

containing not more than 1 part per million of mercury calculated as the metal

(2) Product which is registered under the Control of Drugs and Cosmetics Regulations 1984 containing not more than 0.5 part per million of mercury calculated as the metal

(3) Appliances containing mercury”;

(xxvii) by inserting after the item “Methyl bromide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)	-	All			

(xxviii) by inserting after the item “Miconazole; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Midostaurin	-	All preparations”;					

(xxix) in the item “Narcotic substances, the following: their isomers (whenever the existence of such isomers is possible within the specific chemical designation); their salts; their esters and ethers (whenever the existence of such esters or ethers is possible); the salts of their esters and ethers-”—

(A) by inserting after the item “(DD) Acetylmethadol” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Acryloylfentanyl	-	All preparations”;					

(B) by inserting after the item “(DD) Betameprodine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Betamethadol	-	All preparations”;				

(C) by inserting after the item “(DD) Cannabis, its resin, extracts and tinctures of; cannabin tannate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Carfentanil	-	All preparations”;				

(D) by inserting after the item “(DD) Fentanyl” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) 4-Fluoroisobutyrfentanyl (4-FIBF, pFIBF)	-	All				
(DD) Furanyl fentanyl	-	All				

preparations”;

(E) by inserting after the item “(DD) Norpipanone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Ocfentanil	-	All				

preparations”;

(F) by substituting for the item “(DD) Racemethorplan” the item “(DD) Racemethorphan”;

(G) by inserting after the item “(DD) Sufentanil” and the particulars relating to it the following item:

	<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
		<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
	“(DD) Tetrahydrofuranlyl fentanyl (THF-F)	-	“All preparations”;				
(xxx)	by substituting for the item “Nimetazepam; its salts (DD)” the item “Nimetazepam (DD)”;						
(xxxi)	by substituting for the item “Nitric acid” and the particulars relating to it the following item:						

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Nitric acid	-	-	-	-	9% w/w and over	(1) Under 9% w/w (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxxii) by inserting after the item “Pentoxifylline” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(1-Pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone (UR-144)(DD)	-	-	-	-	-	All preparations”;

(xxxiii) by substituting for the item “Phenols (any member of the series of phenols of which the first member is phenol) and of which the molecular composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phenols (any member of the series of phenols of which the first member is phenol and of which the molecular	-	-	-	-	-	All preparations for diagnostic or therapeutic use unless exempted
					All preparations other than those in Part I or exempted	(1) Paratertiary amyl phenol; tertiary butyl cresol; thymol; carvacrol; soap; tar (coal or wood)

composition varies from member to member by one atom of carbon and two atoms of hydrogen); compounds of phenol with a metal

essential oils; essential oils in which phenols occur naturally

- (2) Strengths under 2.5% w/w of phenols
- (3) 5% w/w of phenols or under in surgical dressings for human or animal use
- (4) Its analogues, homologues, compounds (other than compounds of phenol with a metal), intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxxiv) by substituting for the item “Phosphorus” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Phosphorus white, yellow, red or black	-	-	-	-	All preparations unless exempted	(1) Phosphorus in food, notified cosmetic or registered product under the Control of Drugs and Cosmetics Regulations 1984 (2) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxxv) by substituting for the item “Potassium hydroxide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Potassium hydroxide	-	-	-	-	12% and over unless exempted	(1) Under 12% (2) Accumulators, batteries or

when use as food additive in food

(3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xxxvi) by substituting for the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)” the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) (DD)”;

(xxxvii) by substituting for the item “Safrole” the item “Safrole; includes safrole-rich oil”;

(xxxviii) by inserting after the item “Selenium sulphide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Selexipag	-	All preparations”;				

(xxxix) by substituting for the item “Sodium hydroxide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium hydroxide	-	-	All preparations for therapeutic or diagnostic use	-	All preparations containing 12% and over other than those in Part I or exempted and subject to the provisions of Poisons (Sodium Hydroxide) Regulations, 1962	(1) Under 12% (2) Sodium hydroxide when use as food additive in food (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xl) by substituting for the item “Sulphuric acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sulphuric acid	-	-	-	-	9% w/w and over unless exempted	(1) Under 9% w/w (2) Accumulators; batteries; fire-extinguishers (3) Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xli) by substituting for the item “Thallium; salts of” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Thallium; salts of	-	All medicinal preparations	-	All preparations unless in Group B”;		

(xlii) by substituting for the item “Thionyl Chloride” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Thionyl Chloride	-	-	-	All preparations unless exempted	-	Its analogues, homologues, compounds, intermediates, derivatives, esters, ethers, salts and other substances structurally derived”;

(xliii) by substituting for the item “Thiouracil and other substances structurally derived therefrom” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Thiouracil and other substances structurally derived therefrom	-	All medicinal preparations	-	All		All preparations unless in Group B”;

(xliv) by substituting for the item “L-Tryptophan” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“L-Tryptophan	-	All preparations unless exempted	-	-	-	(1) Preparations containing naturally occurring L-Tryptophan (2) Animal feed or feed additive (3) Food and its added nutrient”;

(xlv) by substituting for the item “Urea” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Urea in medicinal preparation containing 40% and above of urea	-	-	All medicinal preparations”;			

(xlvi) by substituting for the item “13C-Urea” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“13C-Urea in medicinal preparations	-	-	All medicinal preparations”;	and		

(xlvii) by inserting after the item “Vismodegib” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>		<i>Part II Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>
“Vonoprazan	-	All preparations”; and		

(b) in the Appendix to the Poisons List—

(i) in the list of “**Analeptics and Central Stimulants**”—

- (A) by inserting before the item “Amiphenazole; its salts” the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) (DD)”;
- (B) by inserting after the item “Fenetylline” the item “Fluoroamphetamine (4-FA) (DD)”;
- (C) by inserting after the item “Methylphenidate; its salts” the item “Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate (5F-ADB/5F-MDMB-PINACA) (DD)”;
- (D) by inserting after the item “Pemoline; its salts” the item “(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) (DD)”;

- (ii) in the list of “**Analgesics including antipyretic and anti-inflammatory agents**”—
- (A) by substituting for the item “N- [(1S) - 1- (Aminocarbonyl) - 2- methylpropyl] - 1- (cyclohexylmethyl) 1H-indazole- 3- carboxamide (AB-CHMINACA)” the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)”; and
- (B) by substituting for the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- carboxylate (5F-PB-22)” the item “Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22) (DD)”;
- (iii) in the list of “**Antidepressants**”, by substituting for the item “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha- methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item” the item “Hydrazines, benzyl, phenethyl, phenoxyethyl; their alpha-methyl derivatives; acyl derivatives of any of the foregoing substances comprised in this item; salts of any compound comprised in this item for therapeutic use”;
- (iv) in the list of “**Antifungals and Antiprotozoals**”, by substituting for the item “Urea” the item “Urea in medicinal preparation containing 40% and above of urea”;
- (v) in the list of “**Antihypertensives**”, by substituting for the item “Oxyclozanide” the item “Oxyclozanide”;

- (vi) in the list of “**Antineoplastic agents and Immunosuppressants**”—
- (A) by inserting after the item “Anastrozole” the item “Apremilast”;
 - (B) by inserting after the item “Methotrexate; its salts ” the item “Midostaurin”; and
 - (C) by inserting after the item “Trofosfamide” the item “Vedolizumab”;
- (vii) in the list of “**Anti-ulcer agents**”, by inserting after the item “Roxatidine” the item “Vonoprazan”;
- (viii) in the list of “**Industrial and laboratory poisons**”—
- (A) by substituting for the item “Hydrochloric acid” the item “Hydrochloric acid; hydrogen chloride”; and
 - (B) by substituting for the item “Safrole” the item “Safrole; includes safrole-rich oil”;
- (ix) in the list of “**Narcotics**”—
- (A) by inserting after the item “(DD) Acetylmethadol” the item “(DD) Acryloylfentanyl”;
 - (B) by inserting after the item “(DD) Cannabis, its resin, extracts and tinctures of; cannabin tannate” the item “(DD) Carfentanil”;

(C) by inserting after the item “(DD) Fentanyl” the following items:

“(DD) 4-Fluoroisobutyrylfentanyl (4-FIBF, pFIBF)
(DD) Furanyl fentanyl”;

(D) by inserting after the item “(DD) Norpipanone” the item “(DD) Ocfentanil”;

(E) by inserting after the item “(DD) Racemorphan” the item “(DD) Remifentanil”; and

(F) by inserting after the item “(DD) Sufentanil” the item “(DD) Tetrahydrofuranyl fentanyl (THF-F)”;

(x) in the list of “**Tranquillisers**”—

(A) by inserting after the item “Diazepam and other substances structurally derived from 1, 4-benzodiazepine; their salts, unless specified elsewhere in the List” the item “1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (STP/DOM) (DD)”;

(B) by substituting for the item “Flunitrazepam; its salts” the item “Flunitrazepam (DD)”;

(C) by substituting for the item “Nimetazepam; its salts” the item “Nimetazepam (DD)”;

- (D) by substituting for the item “Zolzepam” the item “Zolazepam”; and
- (xi) in the list of “**Miscellaneous**”—
- (A) by deleting the item “Carfentanil citrate”;
- (B) by deleting the item “Furazolidone”;
- (C) by substituting for the item “Phosphorus” the item “Phosphorus white, yellow, red or black”;
- (D) by inserting after the item “Selenium sulphide” the item “Selexipag”; and
- (E) by substituting for the item “13-C Urea” the item “13C-Urea in medicinal preparations”.

Made 25 June 2019
[KKM.R.600-1/1/56 JLD.4(8); PN(PU2)172/XVII]

DATUK SERI DR. DZULKEFLY BIN AHMAD
Minister of Health